Onishi Y, Yamaura T, Tauchi K, Sakamoto T, Tsukada K, Nunome S, Komatsu Y, Saiki I
Department of Pathogenic Biochemistry, Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, Sugitani, Japan.
Biol Pharm Bull. 1998 Jul;21(7):761-5. doi: 10.1248/bpb.21.761.
We investigated the inhibitory effect of oral administration of Juzen-taiho-to, a Kampo Japanese herbal medicine, and its related formulations on the experimental liver and lung metastasis of tumor cells in vivo. Oral administration of Juzen-taiho-to for 7 d before tumor inoculation significantly reduced the number of liver metastatic colonies of colon 26-L5 carcinoma cells and attenuated the increase of liver weight in a dose-dependent manner ranging from 4 to 40 mg/d. Its oral administration for this same period before tumor inoculation also significantly inhibited lung metastasis of B16-BL6 melanoma cells. Juzen-taiho-to originally consisted of 8 crude drugs derived from Shimotsu-to and Shikunshi-to prescriptions together with two crude drugs (Cinnamomi Cortex and Astragali Radix). Oral administration of Shimotsu-to as well as Juzen-taiho-to for 7 d before tumor inoculation resulted in a significant reduction in the number of metastatic colonies and the liver weight as compared with the control, whereas Shikunshi-to did not exhibit such an inhibitory effect. Unsei-in containing four Shimotsu-to constituents was also active in inhibiting liver metastasis. Toki-shakuyaku-san and Ninjin-yoei-to, which include all Shimotsu-to constituents except Rehmanniae Radix and Cnidii Rhizoma, respectively, did not show a significant anti-metastatic effect. Rikkunshi-to and Ninjin-yoei-to, which contain Shikunshi-to constituents, did not affect the inhibition of liver metastasis. Hochu-ekki-to treatment before tumor inoculation also led to a significant inhibition of liver metastasis, probably through an inhibitory mechanism different from Juzen-taiho-to. These results suggest that the anti-metastatic effect of Juzen-taiho-to is partly associated with its Shimotsu-to-derived constituents.
我们研究了口服日本汉方药物十全大补汤及其相关制剂对体内肿瘤细胞实验性肝转移和肺转移的抑制作用。在接种肿瘤前连续7天口服十全大补汤，显著减少了结肠26-L5癌细胞肝转移灶的数量，并以4至40毫克/天的剂量依赖性方式减轻了肝脏重量的增加。在接种肿瘤前的同一时期口服十全大补汤，也显著抑制了B16-BL6黑色素瘤细胞的肺转移。十全大补汤最初由源自四物汤和四君子汤方剂的8味中药材以及两味中药材（肉桂和黄芪）组成。在接种肿瘤前7天口服四物汤以及十全大补汤，与对照组相比，转移灶数量和肝脏重量均显著减少，而四君子汤未表现出这种抑制作用。含有四物汤4种成分的温清饮也具有抑制肝转移的活性。分别包含除地黄和川芎外所有四物汤成分的柴胡疏肝散和人参养荣汤，未显示出显著的抗转移作用。含有四君子汤成分的六君子汤和人参养荣汤，对肝转移的抑制没有影响。在接种肿瘤前给予补中益气汤治疗，也导致肝转移受到显著抑制，其抑制机制可能与十全大补汤不同。这些结果表明，十全大补汤的抗转移作用部分与其源自四物汤的成分有关。
